At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
PF-06835919 25 mgdrug
Likely dose
PF-06835919 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT
In Brief
A Phase 1 clinical trial evaluating PF-06835919 25 mg for Hepatic Impairment and Healthy Participants. Completed, enrolled 23 participants across 3 sites in 3 countries.
Detailed Summary
The study is proposed to characterize the effect of varying degrees of hepatic impairment on the plasma PK of PF-06835919
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment, Healthy Participants
CountriesBelgium, Czechia, Slovakia
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJan 2020
Primary CompletionJul 2021
TodayJul 2026
First PostedDec 10, 2019
Enrollment StartJan 21, 2020
Primary CompletionJul 9, 2021
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.6 years ago
Interventions
PF-06835919 25 mgdrug
PF-06835919 in 25 mg oral tablet will be administered on Day 1